Kazuki Nozawa, Medical Oncologist at Nagoya City University, shared on X:
“Can T-DXd work again after discontinuation?
Our post-hoc analysis of EN-SEMBLE (N=664) identified 26 patients with HER2-positive mBC who were rechallenged with T-DXd.
ORR 27%, median rwPFS 6.5 mo, OS 14.2 mo. Longer rwPFS in those who had stopped T-DXd for reasons other than progression. No ILD on rechallenge.”
Title: Trastuzumab deruxtecan rechallenge in HER2-positive metastatic breast cancer: EN-SEMBLE
Authors: Kazuki Nozawa, Hiroji Iwata, Toru Mukohara, Tetsuhiko Taira, Akiyo Yoshimura, Shigenori E. Nagai, Jun Hashimoto, Kazuo Matsuura, Toshiro Mizuno, Yoshiaki Shinden, Mitsugu Yamamoto, Toshimi Takano, Makoto Wakahara, Hirofumi Terakawa, Takashi Yamanaka, Yasuyuki Kojima, Takahiro Nakayama, Yuji Hirakawa, Kazuhito Shiosakai, Junji Tsurutani
Read the Full Article on The Breast
Other posts featuring Kazuki Nozawa on OncoDaily.
